Author

Raman Garcha

Observed institution: Xencor (United States)

ORCID: 0009-0001-0409-3414

Observed ORCID: 0009-0001-0409-3414

OpenAlex ID: A5077553583

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

2023 · Farhad Ravandi, Asad Bashey, et al. · Blood Advances · 46

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

2022 · Krish Patel, Peter A. Riedell, et al. · Blood · 38

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

2021 · Krish Patel, Jean-Marie Michot, et al. · Blood · 22

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

2026 · David B. Beck, Maël Heiblig, et al. · Journal of Clinical Medicine · 2

MPN-527 Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways

2024 · Srinivas K. Tantravahi, Ashwin Kishtagari, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

2026 · Kevin Byram, Heřman Mann, et al. · Arthritis Care & Research

Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways

2024 · Srinivas K. Tantravahi, Ashwin Kishtagari, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 7

Citation count: 109

H-index: 3

I10-index: 3